Sanofi grap­ples with re­jec­tion of po­ten­tial first-in-class or­phan drug, faults third-par­ty man­u­fac­tur­ing

A snap re­view didn’t lead to a quick OK for Sanofi’s su­tim­limab. A day af­ter the FDA’s sup­posed de­ci­sion date on the or­phan drug, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.